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1. BACKGROUND {#jmv26256-sec-0010}
=============

The fast worldwide spread and outbreak of coronavirus disease 2019 (COVID‐19), which is caused by the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection, has leaded to over 6.4 million infected cases and 370 000 deaths so far.[^1^](#jmv26256-bib-0001){ref-type="ref"} The epidemiologic situation is still severe around the world now due to lack of vaccine and specific antiviral drugs against this highly infectious virus. This has caused anxiety and stress in the general population.[^2^](#jmv26256-bib-0002){ref-type="ref"}, [^3^](#jmv26256-bib-0003){ref-type="ref"}

Based on previous treatments experience of severe acute respiratory syndrome (SARS) and Middle East Respiratory Syndrome (MERS), some potential antiviral drugs have been approved and used urgently in COVID‐19 patients, such as interferon, ribavirin, hydroxychloroquine, lopinavir and ritonavir, umifenovir, and so on.[^4^](#jmv26256-bib-0004){ref-type="ref"}, [^5^](#jmv26256-bib-0005){ref-type="ref"} However, the specific effectiveness of these drugs for COVID‐19 still remains unclear and controversial, especially considering that almost all recent multicenter, randomized, controlled trials (RCTs) failed to observed benefits of them. For instance, Cao et al[^6^](#jmv26256-bib-0006){ref-type="ref"} observed no benefit of lopinavir‐ritonavir treatment in adult patients with severe COVID‐19. Similarly, remdesivir was not associated with significant clinical benefits[^7^](#jmv26256-bib-0007){ref-type="ref"} and hydroxychloroquine did not result in a significantly higher probability of negative conversion.[^8^](#jmv26256-bib-0008){ref-type="ref"}

Recently more and more researchers start focusing on possible efficacy of umifenovir in COVID‐19. Umifenovir is a broad‐spectrum antiviral agent which could effectively inhibit the fusion of virus with host cells and is already licensed for prophylaxis and treatment of influenza.[^9^](#jmv26256-bib-0009){ref-type="ref"} Previous research has elucidated that umifenovir is an efficient inhibitor of SARS‐CoV‐2 in vitro.[^10^](#jmv26256-bib-0010){ref-type="ref"} Nevertheless, little is known about the actual clinical efficacy of umifenovir in vivo due to lack of large‐scale RCTs. Some recent small‐scale clinical studies with limited sample size have drawn controversial conclusions about efficacy of umifenovir for COVID‐19. For example, Wang et al[^11^](#jmv26256-bib-0011){ref-type="ref"} found umifenovir treatment showed tendency to improve the discharging rate and decrease the mortality rate. However, Lian et al[^12^](#jmv26256-bib-0012){ref-type="ref"} demonstrated that umifenovir treatment is not associated with improved outcomes.

Given the emergency of COVID‐19 worldwide and uncertain effectiveness of umifenovir in patients, we conducted this systemic review and meta‐analysis in an attempt to evaluate the efficacy and safety of umifenovir in COVID‐19.

2. MATERIALS AND METHODS {#jmv26256-sec-0020}
========================

2.1. Search strategy {#jmv26256-sec-0030}
--------------------

A systematic and comprehensive search was conducted in six databases: PubMed, Web of Science, Embase, Cochrane Library, China National Knowledge Infrastructure, and medRxiv (<https://www.medrxiv.org>) from 1 December 2019 to 1 June 2020. Potentially relevant studies which reported the efficacy and safety of umifenovir in COVID‐19 were identified. There was no limitation in the publication language. Both Medical Subject Headings terms and free text words were used to increase sensitivity for search strategy. The following search terms were used: "COVID‐19" or "SARS‐CoV‐2" or "novel coronavirus pneumonia" or "novel coronavirus" and "arbidol" or "umifenovir" or "arbidol hydrochloride". The listed references of relevant studies were also manually evaluated to insure a complete search.

All searched results were evaluated according to the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses statement.[^13^](#jmv26256-bib-0013){ref-type="ref"} At first the titles and abstracts were screened to identify related studies, and then full texts were evaluated carefully to determine included studies. The complete search and selection of related studies were performed by two independent researchers. Any disagreement was resolved through the third researcher and even team discussion until consensus was reached.

2.2. Inclusion and exclusion criteria {#jmv26256-sec-0040}
-------------------------------------

All retrospective, prospective observational studies and RCTs of adults investigating the effectiveness of umifenovir in COVID‐19 were considered for inclusion. The following inclusion criteria were used: (a) laboratory‐confirmed COVID‐19 adult patients (18 years or older); (b) patients were divided into umifenovir group in which the patients were all administrated with umifenovir, and control group in which none of patients was administrated with umifenovir; (c) outcomes included at least one of followings: polymerase chain reaction (PCR) negative conversion time and negative rate, rate of symptom alleviation, clinical progression, hospital length of stay (LOS) and adverse events; (d) with informed consent.

The following exclusion criteria were used: (a) studies with insufficient data; (b) commentary, editorials, expert opinions, case reports, letters and reviews; (c) non‐human studies.

2.3. Outcomes and data collection {#jmv26256-sec-0050}
---------------------------------

The primary outcomes of our study included nucleus acid negative conversion time, negative rate of PCR on day 7, negative rate of PCR on day 14 and incidence of composite endpoint (admission to intensive care unit or mechanical ventilation or death). Nucleus acid negative conversion time was defined as the time of positive‐to‐negative conversion of SARS‐CoV‐2 nucleic acid. The negative conversion was confirmed when patients received at least two real time (RT)‐PCR tests taken at least 24‐hour apart and results were all negative. The negative rate on day 7 and day 14 were calculated from diagnosis with COVID‐19, admission into hospital or beginning of treatment, which depends on each individual study. The composite endpoint was used because the three individual components were all considered as serious outcomes of similar infectious diseases.[^14^](#jmv26256-bib-0014){ref-type="ref"}

The secondary outcomes included rate of fever alleviation on day 7, rate of cough alleviation on day 7, hospital LOS and incidence of adverse events. Adverse events included digestive tract reactions (diarrhea, nausea, vomiting, etc), abnormal liver function tests or renal function tests, psychiatric symptom reactions (depression, acute confusion, etc).

Data were extracted by 2 investigators independently. Similarly, any disagreement was resolved through third investigator and team discussion until consensus was reached. Data were retrieved by using an Excel spreadsheet (Microsoft Corporation, Redmond, WA). The following information was extracted from each study: first author and publication year, study design, region, number of patients, specific therapies in umifenovir group and control group, key outcomes.

3. STATISTICAL ANALYSES {#jmv26256-sec-0060}
=======================

Data syntheses were completed by using Cochrane systematic review software Review Manager (RevMan; Version 5.2; The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, 2014). The results were displayed in forest plots, and statistical significance was defined as *P* \< .05. Based on the immunological study, the continuous variables were reported as mean and SD,[^15^](#jmv26256-bib-0015){ref-type="ref"}, [^16^](#jmv26256-bib-0016){ref-type="ref"} whereas dichotomous variables were reported as frequency and proportion.[^17^](#jmv26256-bib-0017){ref-type="ref"} Statistical heterogeneity among included studies was evaluated via Cochran Q test and Higgins I[^2^](#jmv26256-bib-0002){ref-type="ref"} statistic.[^18^](#jmv26256-bib-0018){ref-type="ref"} Significant heterogeneity was rendered as *P* \< .1 or *I* ^2^ \> 50%. The random‐effects model was used to calculate the pooled effects if significant heterogeneity was observed to generalize findings beyond the included studies by assuming that the selected studies are random samples from a larger population,[^19^](#jmv26256-bib-0019){ref-type="ref"} otherwise fixed‐effects model was used. Mean difference (MD) and 95% confidence interval (CI) were calculated for continuous data, with risk ratio (RR) and 95% CI for dichotomous data.

To investigate the potential sources of heterogeneity for primary outcomes, we performed sensitivity analysis to further verify conclusions of meta‐analysis by excluding some low‐quality and dubious studies, and subgroup analysis in terms of different sample size, study design, and administrations of antiviral drugs in control group.

3.1. Quality assessment {#jmv26256-sec-0070}
-----------------------

We used the Newcastle‐Ottawa quality assessment scale (NOS) to assess quality of the included studies.[^20^](#jmv26256-bib-0020){ref-type="ref"} The NOS consists of three parameters of quality: selection, comparability, and outcome. A score of 0 to 9 was allocated to each study. Generally, studies which earned 6 or higher points were regarded as high‐quality studies. Besides, the certainty of evidence at the outcome level was assessed using the GRADE approach.[^21^](#jmv26256-bib-0021){ref-type="ref"} Quality assessment was also conducted by two independent researchers.

4. RESULTS {#jmv26256-sec-0080}
==========

A total of 290 records from all databases and other sources were identified. After duplicates removal, 137 records were screened for title and abstract. Then, 28 full‐text studies were further assessed for eligibility, and eventually 12 studies were enrolled in our final analysis, including 10 retrospective studies[^11^](#jmv26256-bib-0011){ref-type="ref"}, [^12^](#jmv26256-bib-0012){ref-type="ref"}, [^22^](#jmv26256-bib-0022){ref-type="ref"}, [^23^](#jmv26256-bib-0023){ref-type="ref"}, [^24^](#jmv26256-bib-0024){ref-type="ref"}, [^25^](#jmv26256-bib-0025){ref-type="ref"}, [^26^](#jmv26256-bib-0026){ref-type="ref"}, [^27^](#jmv26256-bib-0027){ref-type="ref"}, [^28^](#jmv26256-bib-0028){ref-type="ref"}, [^29^](#jmv26256-bib-0029){ref-type="ref"} and 2 randomized controlled trials[^30^](#jmv26256-bib-0030){ref-type="ref"}, [^31^](#jmv26256-bib-0031){ref-type="ref"} (Figure [1](#jmv26256-fig-0001){ref-type="fig"}).

![Study flow diagram](JMV-9999-na-g001){#jmv26256-fig-0001}

4.1. Study description {#jmv26256-sec-0090}
----------------------

A total of 1052 patients were pooled from all included studies in our meta‐analysis. All studies were conducted in China. The sample size of each study varied from 32 to 236 patients. Among six included studies, the patients in control group were only administrated with standard care. And in the other six studies, control group were administrated with standard care plus other antiviral drugs, such as lopinavir/ritonavir, interferon, favipiravir, and so on. As for quality assessment, all eight studies earned at least six points. Details of characteristics of included studies are shown in Table [1](#jmv26256-tbl-0001){ref-type="table"}.

###### 

Characteristics of included studies

  Reference                                              Study design                             Region                      No. of patients   Median age of patients, y   Severity of patients at admission                    Intervention                                                                     Control                                                  Outcomes                                                                                                                             NOS
  ------------------------------------------------------ ---------------------------------------- --------------------------- ----------------- --------------------------- ---------------------------------------------------- -------------------------------------------------------------------------------- -------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------ -----
  Zhu et al[^22^](#jmv26256-bib-0022){ref-type="ref"}    Retrospective                            Jiangsu, China              50                26                          NA                                                   Standard care plus arbidol (0.2 g tid)                                           Standard care plus lopinavir/ritonavir                   Negative conversion time, negative rate on day 7 and day 14                                                                          7
  Chen et al[^30^](#jmv26256-bib-0030){ref-type="ref"}   Multicenter, open‐label, RCT             Hubei, China                236               NA                          Not severe/critical patients                         Standard care plus arbidol (0.2 g tid)                                           Standard care plus favipiravir                           Rate of symptom alleviation on day 7, Incidence of composite endpoint and adverse events,                                            8
  Wen et al[^25^](#jmv26256-bib-0025){ref-type="ref"}    Retrospective                            Guangzhou, China            94                54                          NA                                                   Standard care plus arbidol (0.2 g tid)                                           Standard care                                            Negative rate of PCR on day 7 and day 14, Rate of symptom alleviation on day 7, Incidence of composite endpoint and adverse events   7
  Chen et al[^26^](#jmv26256-bib-0026){ref-type="ref"}   Retrospective                            Shanghai, China             82                44                          NA                                                   Standard care plus IFN‐α2b and arbidol (0.2 g tid)                               Standard care plus IFN‐α2b                               Negative rate on day 7, Incidence of composite endpoint and adverse events,                                                          8
  Li et al[^31^](#jmv26256-bib-0031){ref-type="ref"}     Exploratory RCT                          Guangzhou, China            52                50                          mild/moderate patients                               Standard care plus arbidol (0.2 g tid)                                           Standard care                                            negative conversion time, Negative rate of PCR on day 7 and day 14, Rate of symptom alleviation on day 7                             9
  Xu et al[^24^](#jmv26256-bib-0024){ref-type="ref"}     Multicenter retrospective cohort study   Hubei and Shenzhen, China   141               51                          Not severe/critical patients (without ventilation)   Standard care plus inhaled IFN‐α2b (bid, 5 ×10\*5 IU) and arbidol (0.2gtid)      Standard care plus inhaled IFN‐α2b (bid, 5 ×10\*5 IU)    negative conversion time                                                                                                             6
  Deng et al[^28^](#jmv26256-bib-0028){ref-type="ref"}   Retrospective cohort study               Guangdong Province, China   33                41                          Not severe/critical patients (without ventilation)   Standard care plus lopinavir/ritonavir (0.4/0.1 g bid) and arbidol (0.2 g tid)   Standard care plus lopinavir/ritonavir (0.4/0.1 g bid)   Negative rate on day 7 and day 14                                                                                                    8
  Lan et al[^29^](#jmv26256-bib-0029){ref-type="ref"}    Retrospective observational study        Zhejiang, China.            73                52                          non‐ICU patients                                     Standard care plus lopinavir/ritonavir (0.4/0.1 g bid) and arbidol (0.2 g tid)   Standard care plus lopinavir/ritonavir (0.4/0.1 g bid)   negative conversion time, Incidence of composite endpoint, Hospital length of stay                                                   7
  Liu et al[^27^](#jmv26256-bib-0027){ref-type="ref"}    Retrospective                            Wuhan, China                32                44                          NA                                                   Standard care plus abidor (0.2 g tid)                                            Standard care                                            negative conversion time, Hospital length of stay, Incidence of composite endpoint                                                   6
  Lian et al[^12^](#jmv26256-bib-0012){ref-type="ref"}   Retrospective                            Wuhan, China                81                60                          non‐ICU patients                                     Standard care plus umifenovir (0.2 g tid)                                        Standard care                                            Hospital length of stay, negative conversion time                                                                                    8
  Wang et al[^11^](#jmv26256-bib-0011){ref-type="ref"}   Retrospective                            Wuhan, China                69                42                          NA                                                   Standard care plus arbidol                                                       Standard care                                            Incidence of composite endpoint                                                                                                      6
  Chen et al[^23^](#jmv26256-bib-0023){ref-type="ref"}   Retrospective                            Guangzhou, China            109               48                          NA                                                   Standard care plus arbidol                                                       Standard care                                            negative conversion time, Negative rate of PCR on day 14, Hospital length of stay                                                    9

Abbreviations: ICU, intensive care unit; IFN: interferon; NA, not acquired; RCT, randomized controlled trial.

*Note*: bid, twice a day; composite endpoint, admission to ICU or mechanical ventilation or death; tid, three times a day.
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4.2. Outcomes {#jmv26256-sec-0100}
-------------

A total of 7 studies[^12^](#jmv26256-bib-0012){ref-type="ref"}, [^22^](#jmv26256-bib-0022){ref-type="ref"}, [^23^](#jmv26256-bib-0023){ref-type="ref"}, [^24^](#jmv26256-bib-0024){ref-type="ref"}, [^27^](#jmv26256-bib-0027){ref-type="ref"}, [^29^](#jmv26256-bib-0029){ref-type="ref"}, [^31^](#jmv26256-bib-0031){ref-type="ref"} reported nucleus acid negative conversion time (Figure [2](#jmv26256-fig-0002){ref-type="fig"}). There was no significant difference of negative conversion time between umifenovir group and control group (MD: 0.09; 95% CI: −1.48 to 1.65; *I* ^2^ = 89%). There were six studies[^12^](#jmv26256-bib-0012){ref-type="ref"}, [^22^](#jmv26256-bib-0022){ref-type="ref"}, [^25^](#jmv26256-bib-0025){ref-type="ref"}, [^26^](#jmv26256-bib-0026){ref-type="ref"}, [^28^](#jmv26256-bib-0028){ref-type="ref"}, [^31^](#jmv26256-bib-0031){ref-type="ref"} and five studies[^22^](#jmv26256-bib-0022){ref-type="ref"}, [^23^](#jmv26256-bib-0023){ref-type="ref"}, [^25^](#jmv26256-bib-0025){ref-type="ref"}, [^28^](#jmv26256-bib-0028){ref-type="ref"}, [^31^](#jmv26256-bib-0031){ref-type="ref"} which reported negative rate of PCR on day 7 and day 14, respectively. Umifenovir was not associated with higher negative rate on day 7(RR:1.09; 95% CI: 0.91 to 1.31; I^2^ = 44%). However, umifenovir could increase negative rate of PCR on day 14 (RR:1.27; 95% CI: 1.04 to 1.55; I^2^ = 63%; Figure [3](#jmv26256-fig-0003){ref-type="fig"}). The pooled results of 6 studies[^11^](#jmv26256-bib-0011){ref-type="ref"}, [^25^](#jmv26256-bib-0025){ref-type="ref"}, [^26^](#jmv26256-bib-0026){ref-type="ref"}, [^27^](#jmv26256-bib-0027){ref-type="ref"}, [^29^](#jmv26256-bib-0029){ref-type="ref"}, [^30^](#jmv26256-bib-0030){ref-type="ref"} revealed that umifenovir was not associated with incidence of composite endpoint (RR:1.20; 95% CI: 0.61 to 2.37; *I* ^2^ = 38%; Figure [4](#jmv26256-fig-0004){ref-type="fig"}).

![Forest plot for nucleus acid negative conversion time between umifenovir group and control group](JMV-9999-na-g002){#jmv26256-fig-0002}

![Forest plot for negative rate of polymerase chain reaction on day 7 and day 14 between umifenovir group and control group](JMV-9999-na-g003){#jmv26256-fig-0003}

![Forest plot for incidence of composite endpoint between umifenovir group and control group](JMV-9999-na-g004){#jmv26256-fig-0004}

Furthermore, our meta‐analysis showed that there was no significant association between umifenovir and secondary outcomes: rate of fever alleviation on day 7 (RR:1.00; 95% CI: 0.91 to 1.10; *I* ^2^ = 0%); rate of cough alleviation on day 7 (RR:1.00; 95% CI: 0.85 to 1.18; *I* ^2^ = 0%; Figure [5](#jmv26256-fig-0005){ref-type="fig"}) and hospital LOS (MD: 1.34; 95% CI: −2.08 to 4.76; *I* ^2^ = 97%; Figure [6](#jmv26256-fig-0006){ref-type="fig"}). Last but not the least, four studies[^25^](#jmv26256-bib-0025){ref-type="ref"}, [^26^](#jmv26256-bib-0026){ref-type="ref"}, [^30^](#jmv26256-bib-0030){ref-type="ref"}, [^31^](#jmv26256-bib-0031){ref-type="ref"} reported the safety of umifenovir. The pooled results showed that use of umifenovir was safe in COVID‐19 patients (RR for incidence of adverse events:1.29; 95% CI: 0.57 to 2.92; *I* ^2^ = 56%; Figure [7](#jmv26256-fig-0007){ref-type="fig"}). According to the GRADE approach, these outcomes were all low certainty of evidence.

![Forest plot for rate of fever alleviation and cough alleviation on day 7 between umifenovir group and control group](JMV-9999-na-g005){#jmv26256-fig-0005}

![Forest plot for hospital length of stay between umifenovir group and control group](JMV-9999-na-g006){#jmv26256-fig-0006}

![Forest plot for incidence of adverse events between umifenovir group and control group](JMV-9999-na-g007){#jmv26256-fig-0007}

4.3. Sensitivity analysis and subgroup analysis {#jmv26256-sec-0110}
-----------------------------------------------

Among these included studies, the study of Wen et al[^25^](#jmv26256-bib-0025){ref-type="ref"} and study of Chen et al[^23^](#jmv26256-bib-0023){ref-type="ref"} were both conducted in Guangzhou Eighth People\'s Hospital, China. It is possible that some data of confirmed COVID‐19 patients was duplicated. After team discussion, we decided to include both two studies in current meta‐analysis because their key outcomes were almost completely different. Besides, we noticed that the study of Wang et al[^11^](#jmv26256-bib-0011){ref-type="ref"} was mainly conducted to summary clinical features of 69 cases with COVID‐19 in Wuhan, China. As a result, the effectiveness of umifenovir was not a primary outcome, which means some bias might exist and affect the pooled results. As for four primary outcomes, the sensitivity analysis still had similar results with pooled results, after excluding the study of Wen et al and Wang et al (Table [2](#jmv26256-tbl-0002){ref-type="table"}).

###### 

Sensitivity analysis and subgroup analysis of primary outcomes

  Analysis                                    No. of studies   Nucleus acid negative conversion time (MD)(95%CI)   *P* interaction   Negative rate of PCR on day 7 (RR)(95%CI)   Negative rate of PCR on day 14 (RR)(95%CI)   *P* interaction   Incidence of composite endpoint (RR)(95%CI)
  ------------------------------------------- ---------------- --------------------------------------------------- ----------------- ------------------------------------------- -------------------------------------------- ----------------- ---------------------------------------------
  Sensitivity analysis                        10               0.09(−1.48, 1.65)                                                     1.18(0.88, 1.57)                            1.35(1.03, 1.77)                                               1.54(0.54, 4.4)
  Sample size                                                                                                      .38                                                                                                        .10               
  ≥100                                        3                1.49(−1.99, 4.96)                                                     NA                                          1.04(0.84, 1.29)                                               3.87(0.44, 34.08)
  \<100                                       9                −0.38(−2.61, 1.86)                                                    1.09(0.91, 1.31)                            1.37(1.07, 1.74)                                               0.99(0.47, 2.06)
  Study design                                                                                                     .84                                                                                                        .64               
  RCT                                         2                −0.2(−3.07, 2.67)                                                     0.9(0.44, 1.84)                             1.2(0.9, 1.59)                                                 3.87(0.44, 34.08)
  retrospective                               10               0.14(−1.57, 1.84)                                                     1.16(0.86, 1.56)                            1.31(1.02, 1.69)                                               0.99(0.47, 2.06)
  Antiviral drugs                                                                                                  .93                                                                                                        .001              
  Control group without any antiviral drugs   6                0.03(−1.59, 1.65)                                                     0.89(0.69, 1.15)                            1.10(0.96, 1.25)                                               0.75(0.08, 7.43)
  Control group with other antiviral drugs    6                0.64(−3.82, 5.10)                                                     1.57(0.85, 2.90)                            1.75(1.35, 2.28)                                               1.73(0.55, 5.47)

Abbreviations: CI, confidence interval; MD, mean difference; NA, not acquired; RR, relative risk; RCT, randomized controlled trial.
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We also performed subgroup analysis to explore the impacts of different sample size, study design, and administrations of antiviral drugs in control group on pooled results. We further conducted a test of interaction for the results with huge heterogeneity (negative conversion time and negative rate of PCR on day 14). As shown in table [2](#jmv26256-tbl-0002){ref-type="table"}, the results of subgroup analysis were similar with pooled results. Generally, our conclusion is relatively stable and reliable.

4.4. Publication bias {#jmv26256-sec-0120}
---------------------

Given that only under 10 studies were included in each outcome in our meta‐analysis, the approaches to evaluate publication bias might have limited efficacy. Therefore, publication bias was not assessed.

5. DISCUSSION {#jmv26256-sec-0130}
=============

It is acknowledged most of COVID‐19 patients are now mainly receiving supportive and symptomatic therapies due to lack of clinical evidence for effective antiviral drugs against SARS‐coV‐2. Umifenovir has been recommended for the treatment of COVID‐19 in some countries currently. However, the clinical evidence is still limited.

To our knowledge, this is the first systematic review and meta‐analysis to assess exclusively efficacy and safety of umifenovir for COVID‐19. Liu et al[^32^](#jmv26256-bib-0032){ref-type="ref"} have ever conducted a systematic review of efficacy of umifenovir for COVID‐19 based on evidence in studies of SARS‐CoV‐2 and other acute viral infections. They included only four studies and concluded that there was limited evidence of uncertain effects of treatment using umifenovir in COVID‐19 patients. We included more studies and conducted further detailed meta‐analysis. Our main finding is that umifenovir is associated with higher negative rate of PCR on day 14 in COVID‐19 adult patients and this finding may be useful for countries with low socioeconomic status.[^33^](#jmv26256-bib-0033){ref-type="ref"} However, umifenovir is not associated with nucleus acid negative conversion time, negative rate of PCR on day 7, incidence of composite endpoint, rate of symptom alleviation on day 7, hospital LOS or incidence of adverse events. The reasons for increased PCR negative rate on day 14 are still unclear so far. According to previous reports, the median seroconversion time for antibodies, IgM and IgG were day‐11, day‐12, and day‐14, respectively[^34^](#jmv26256-bib-0034){ref-type="ref"} and the median duration of viral shedding was 20 days in clinical course of COVID‐19.[^35^](#jmv26256-bib-0035){ref-type="ref"} Therefore, it is possible that the effects of umifenovir on negative conversion rate are only observed since 2 or 3 weeks after onset.

Umifenovir is a small indole‐derivative molecule which can simultaneously block virus' entry into target cells, inhibit synthesis of viral RNA, and stimulate immune via induction of serum interferon and activation of phagocytes.[^9^](#jmv26256-bib-0009){ref-type="ref"} Umifenovir has also direct and superior antiviral effects in early stage of viral replication in vitro for SARS.[^36^](#jmv26256-bib-0036){ref-type="ref"} Nevertheless, based on previous studies, the efficacy of umifenovir for COVID‐19 in vivo is unsatisfactory. One plausible explanation is that higher dose is needed to achieve equal suppression effect of SARS‐CoV‐2 in patients with that in vitro. For example, Sheahan et al[^37^](#jmv26256-bib-0037){ref-type="ref"} have elucidated remdesivir and IFN have superior antiviral activity against MERS‐CoV in vitro. However, this assumption needs to be verified in future studies.

In China, the standard of discharge includes improvement of clinical symptoms and CT, and at least two consecutive negative results of PCR.[^38^](#jmv26256-bib-0038){ref-type="ref"} Thus, the negative conversion time and negative rate were both defined as primary outcomes in meta‐analysis. Additionally, the composite endpoint which represents the clinical progression of illness in COVID‐19 patients was also considered as a primary outcome. Our preliminary meta‐analysis indicates that umifenovir has good safety and tolerability but limited efficacy. It should be noted that there were also some other outcome variables which we did not use in current meta‐analysis. For example, it is reported umifenovir was not superior compared with conventional supportive therapies in radiology improvement (via chest CT scores), clinical recovery rate on day 7, or cure rate.[^12^](#jmv26256-bib-0012){ref-type="ref"}, [^29^](#jmv26256-bib-0029){ref-type="ref"}, [^30^](#jmv26256-bib-0030){ref-type="ref"}, [^31^](#jmv26256-bib-0031){ref-type="ref"} Because of the overall results, and particularly the results in patient‐important outcomes, there is currently no place for the use of umifenovir in COVID patients.

There were also several similar original studies and reviews which arrived at similar conclusions. Peng et al[^39^](#jmv26256-bib-0039){ref-type="ref"} showed that umifenovir was not associated with hospital LOS (HR: 1.62; 95%CI: 0.37‐7.01) or time of SARS‐CoV‐2 RNA clearance (HR: 0.51; 95%CI: 0.11‐2.30) in multivariate analysis among children patients with COVID‐19. Zhong et al[^40^](#jmv26256-bib-0040){ref-type="ref"} have conducted a comprehensive meta‐analysis of therapies for SARS, MERS, and COVID‐19 and found umifenovir did not show a superior ability in virological eradication compared with control group (RR: 1.07; 95%: 0.83‐1.39).

Our study has several limitations. Firstly, most of included studies were retrospective cohort studies and all studies were conducted in China, which might lead to potential selection bias. It has to be acknowledged that the RCTs of umifenovir in COVID‐19 are still deficient so far. Therefore, we decided to include both observational studies and RCTs in this meta‐analysis in an attempt to provide a preliminary conclusion for the use of umifenovir in COVID‐19. Several ongoing clinical trials evaluating efficacy of umifenovir in COVID‐19 (NCT04260594, NCT04255017, NCT04252885) might clarify this issue in the future. Then, some outcomes included a small sample size of patients. Thirdly, the variations in population, severity of illness, timing of treatment, dosage, co‐treatments among included studies might lead to huge heterogeneity and influence our results. It should be noted that the antiviral drugs in the control group may also be contributing to heterogeneity, which was showed in the subgroup analysis for the results of negative rate of PCR on day 14. Nevertheless, we were not able to conduct further analysis because original individual data of patients' age and severity were not available.

Considering low quality and certainty of evidence and huge heterogeneity, it is difficult to draw a clear conclusion about the advantages of umifenovir for COVID‐19 up to now. However, to some degree, our conclusions might help physicians to comprehensively understand the mechanisms, effectiveness, indications of umifenovir in COVID‐19. More basic researchers are also needed to reveal the association of umifenovir, immunity of host and clearance of SARS‐coV‐2.

6. CONCLUSIONS {#jmv26256-sec-0140}
==============

We found that umifenovir was safe and associated with higher negative rate of PCR on day 14 in laboratory‐confirmed COVID‐19 adult patients. However, it could not significantly shorten nucleus acid negative conversion time or hospital LOS, improve symptoms or decrease risk of disease progression. In conclusion, there is no evidence to support the use of umifenovir for improving patient‐important outcomes in patients with COVID‐19. Our conclusions need to be verified in future studies.
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